2026Q1
| Insider | Role (last 12 mo) | Shares held | Filed at |
|---|---|---|---|
| Genexine Inc. | 10% Owner | 56,818,175 | Jul 28, 2021 |
| Kim Young-Jin | Director | 8,423,386 | Nov 21, 2025 |
| XOMA Corp | — | 8,093,010 | Apr 30, 2018 |
| Mantripragada Sankaram | — | 6,000,000 | Feb 8, 2013 |
| Handok, Inc. | Director | 5,942,617 | Mar 19, 2024 |
| Exec date | Filing date | Insider | Role | Signal | Confidence | Shares | % of shares | Under plan? | Amount (USD) |
|---|---|---|---|---|---|---|---|---|---|
| Mar 2, 2026 | Mar 4, 2026 | ROBERTS BRIAN KENNETH | Chief Medical Officer | Sell | 46.3 | -11,439 | -3.53% | ✗ | $34.2K |
| Mar 2, 2026 | Mar 4, 2026 | Evans Daron | CFO | Sell | 46.3 | -11,438 | -2.23% | ✗ | $34.2K |
| Mar 2, 2026 | Mar 4, 2026 | Elam Nevan C | CEO | Sell | 42.5 | -27,618 | -4.31% | ✗ | $82.6K |
| Dec 16, 2025 | Dec 17, 2025 | Hogenhuis Wladimir | Director | Buy | 82.5 | +5,650 | 4.96% | ✗ | $9.5K |
| Dec 16, 2025 | Dec 17, 2025 | ROBERTS BRIAN KENNETH | Chief Medical Officer | Buy | 86.3 | +28,000 | 9.46% | ✗ | $47.6K |
| Dec 15, 2025 | Dec 15, 2025 | Evans Daron | CFO | Buy | 90.0 | +45,000 | 9.62% | ✗ | $79.6K |
| Dec 15, 2025 | Dec 15, 2025 | Elam Nevan C | CEO | Buy | 90.0 | +32,000 | 5.25% | ✗ | $50.9K |
| Dec 15, 2025 | Dec 15, 2025 | Karnawat Sunil Ratilal | Chief Commercial Officer | Buy | 91.3 | +12,100 | 17.45% | ✗ | $19.6K |
| Nov 19, 2025 | Nov 21, 2025 | ROBERTS BRIAN KENNETH | Chief Medical Officer | Neutral | 90.0 | +123,000 | 71.16% | ✗ | - |
| Nov 19, 2025 | Nov 21, 2025 | Karnawat Sunil Ratilal | Chief Commercial Officer | Neutral | 90.0 | +32,000 | 85.70% | ✗ | - |
| Nov 19, 2025 | Nov 21, 2025 | Elam Nevan C | CEO | Neutral | 90.0 | +317,000 | 108.52% | ✗ | - |
| Nov 19, 2025 | Nov 21, 2025 | Evans Daron | CFO | Neutral | 90.0 | +107,000 | 29.65% | ✗ | - |
| Nov 19, 2025 | Nov 21, 2025 | KREHER NERISSA | Director | Neutral | 90.0 | +21,000 | 55.89% | ✗ | - |
| Nov 19, 2025 | Nov 21, 2025 | Hogenhuis Wladimir | Director | Neutral | 90.0 | +21,000 | 22.57% | ✗ | - |
| Nov 19, 2025 | Nov 21, 2025 | Harris Erik | Director | Neutral | 90.0 | +21,000 | 100.00% | ✗ | - |
| Nov 19, 2025 | Nov 21, 2025 | Kim Young-Jin | Director | Neutral | 60.0 | +21,000 | 0.24% | ✗ | - |
| Nov 19, 2025 | Nov 21, 2025 | FAUCHET PHILIPPE | Director | Neutral | 90.0 | +21,000 | 60.87% | ✗ | - |
| Nov 19, 2025 | Nov 21, 2025 | Labrucherie Gil M | Director | Neutral | 90.0 | +21,000 | 23.84% | ✗ | - |
| Aug 18, 2025 | Aug 27, 2025 | Karnawat Sunil Ratilal | Chief Commercial Officer | Neutral | 90.0 | +25,000 | 202.59% | ✗ | - |
| Aug 27, 2025 | Karnawat Sunil Ratilal | Chief Commercial Officer | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Jun 25, 2025 | Jun 26, 2025 | ROBERTS BRIAN KENNETH | Chief Medical Officer | Buy | 91.3 | +2,500 | 17.39% | ✗ | $10.9K |
| Jun 24, 2025 | Jun 24, 2025 | Evans Daron | CFO | Buy | 78.8 | +5,000 | 1.40% | ✗ | $20.3K |
| Jun 13, 2025 | Jun 23, 2025 | Kim Young-Jin | Director | Buy | 100.0 | +1,230,769 | 16.76% | ✗ | $4M |
| Jun 13, 2025 | Jun 23, 2025 | KREHER NERISSA | Director | Buy | 85.0 | +3,076 | 8.92% | ✗ | $10K |
| Jun 10, 2025 | Jun 13, 2025 | KREHER NERISSA | Director | Neutral | 90.0 | +9,000 | 35.29% | ✗ | - |
| Jun 10, 2025 | Jun 13, 2025 | Labrucherie Gil M | Director | Neutral | 90.0 | +9,000 | 11.38% | ✗ | - |
| Jun 10, 2025 | Jun 13, 2025 | Hogenhuis Wladimir | Director | Neutral | 90.0 | +9,000 | 10.71% | ✗ | - |
| Jun 10, 2025 | Jun 12, 2025 | Kim Young-Jin | Director | Neutral | 55.0 | +9,000 | 0.12% | ✗ | - |
| Jun 10, 2025 | Jun 12, 2025 | Evans Daron | CFO | Neutral | 85.0 | +26,000 | 7.88% | ✗ | - |
| Jun 10, 2025 | Jun 12, 2025 | FAUCHET PHILIPPE | Director | Neutral | 90.0 | +9,000 | 35.29% | ✗ | - |
| Jun 10, 2025 | Jun 12, 2025 | ROBERTS BRIAN KENNETH | Chief Medical Officer | Neutral | 90.0 | +26,000 | 17.84% | ✗ | - |
| Jun 10, 2025 | Jun 12, 2025 | Elam Nevan C | CEO | Neutral | 90.0 | +68,000 | 30.34% | ✗ | - |
| Mar 31, 2025 | Apr 1, 2025 | Hogenhuis Wladimir | Director | Buy | 86.3 | +6,758 | 8.75% | ✗ | $19.7K |
| Mar 27, 2025 | Mar 31, 2025 | Elam Nevan C | CEO | Buy | 86.3 | +12,302 | 5.81% | ✗ | $35K |
| Mar 26, 2025 | Mar 28, 2025 | Evans Daron | CFO | Buy | 90.0 | +20,000 | 6.45% | ✗ | $57.7K |
| Mar 25, 2025 | Mar 26, 2025 | Harris Erik | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Mar 26, 2025 | Harris Erik | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Feb 16, 2025 | Feb 20, 2025 | Hogenhuis Wladimir | Director | Buy | 91.3 | +35,500 | 85.00% | ✗ | $47K |
| Feb 16, 2025 | Feb 20, 2025 | Labrucherie Gil M | Director | Neutral | 90.0 | +25,500 | 47.60% | ✗ | - |
| Feb 16, 2025 | Feb 19, 2025 | Evans Daron | CFO | Neutral | 90.0 | +77,000 | 33.06% | ✗ | - |
| Feb 16, 2025 | Feb 19, 2025 | KREHER NERISSA | Director | Neutral | 90.0 | +25,500 | 100.00% | ✗ | - |
| Feb 16, 2025 | Feb 19, 2025 | Kim Young-Jin | Director | Buy | 100.0 | +1,275,500 | 21.05% | ✗ | $5M |
| Feb 16, 2025 | Feb 19, 2025 | ROBERTS BRIAN KENNETH | Chief Medical Officer | Neutral | 90.0 | +77,000 | 112.04% | ✗ | - |
| Feb 16, 2025 | Feb 19, 2025 | Elam Nevan C | CEO | Neutral | 90.0 | +204,000 | 2609.70% | ✗ | - |
| Feb 16, 2025 | Feb 19, 2025 | FAUCHET PHILIPPE | Director | Neutral | 90.0 | +25,500 | 100.00% | ✗ | - |
| Dec 18, 2024 | Dec 18, 2024 | Evans Daron | CFO | Buy | 83.8 | +10,000 | 4.49% | ✗ | $42.9K |
| Dec 12, 2024 | Dec 12, 2024 | Evans Daron | CFO | Buy | 83.8 | +9,000 | 4.21% | ✗ | $41.4K |
| Dec 9, 2025 | Dec 10, 2024 | Evans Daron | CFO | Buy | 90.0 | +10,549 | 5.19% | ✗ | $53.2K |
| Sep 24, 2024 | Sep 24, 2024 | Hogenhuis Wladimir | Director | Buy | 91.3 | +4,259 | 11.35% | ✗ | $20K |
| Sep 23, 2024 | Sep 24, 2024 | Evans Daron | CFO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 25, 2024 | Jun 27, 2024 | Hogenhuis Wladimir | Director | Buy | 91.3 | +4,815 | 14.73% | ✗ | $20K |
| Jun 14, 2024 | Jun 14, 2024 | ROBERTS BRIAN KENNETH | Chief Medical Officer | Buy | 91.3 | +7,600 | 12.43% | ✗ | $29.7K |
| Jun 14, 2024 | Jun 14, 2024 | Evans Daron | CFO | Buy | 95.0 | +40,000 | 24.49% | ✗ | $161.6K |
| May 29, 2024 | May 31, 2024 | Evans Daron | CFO | Buy | 60.0 | +451 | 0.28% | ✗ | $1.6K |
| May 23, 2024 | May 28, 2024 | ROBERTS BRIAN KENNETH | Chief Medical Officer | Buy | 91.3 | +7,500 | 13.99% | ✗ | $20.1K |
| May 23, 2024 | May 28, 2024 | Evans Daron | CFO | Buy | 77.5 | +3,000 | 1.88% | ✗ | $9.7K |
| Mar 28, 2024 | Mar 29, 2024 | ROBERTS BRIAN KENNETH | Chief Medical Officer | Buy | 67.5 | +500 | 0.94% | ✗ | $1.3K |
| Oct 15, 2021 | Mar 19, 2024 | HANDOK, INC. | Director | Buy | 100.0 | +3,927,126 | 194.85% | ✗ | $17M |
| Mar 15, 2024 | Mar 19, 2024 | Evans Daron | CFO | Buy | 91.3 | +20,000 | 14.30% | ✗ | $33.8K |
| Mar 14, 2024 | Mar 18, 2024 | ROBERTS BRIAN KENNETH | Chief Medical Officer | Buy | 91.3 | +10,000 | 23.19% | ✗ | $18.8K |
| Mar 7, 2024 | Mar 18, 2024 | ROBERTS BRIAN KENNETH | Chief Medical Officer | Buy | 77.5 | +500 | 1.17% | ✗ | $925 |
| Jul 22, 2022 | Mar 14, 2024 | Kim Young-Jin | Director | Buy | 85.0 | +115,450 | 1.94% | ✗ | $369.9K |
| Mar 7, 2024 | Mar 11, 2024 | ROBERTS BRIAN KENNETH | Chief Medical Officer | Buy | 77.5 | +500 | 1.18% | ✗ | $925 |
| Mar 8, 2024 | Mar 8, 2024 | Evans Daron | CFO | Buy | 95.0 | +50,000 | 55.62% | ✗ | $96.3K |
| Feb 26, 2024 | Feb 28, 2024 | Elam Nevan C | CEO | Buy | 90.0 | +5,000 | 177.49% | ✗ | $8.4K |
| Feb 23, 2024 | Feb 27, 2024 | ROBERTS BRIAN KENNETH | Chief Medical Officer | Buy | 91.3 | +8,000 | 23.15% | ✗ | $13.5K |
| Feb 16, 2024 | Feb 21, 2024 | ROBERTS BRIAN KENNETH | Chief Medical Officer | Buy | 90.0 | +7,000 | 25.41% | ✗ | $9.1K |
| Feb 16, 2024 | Feb 20, 2024 | Evans Daron | CFO | Buy | 95.0 | +50,900 | 130.51% | ✗ | $66.7K |
| Jan 23, 2024 | Jan 25, 2024 | Evans Daron | CFO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jan 25, 2024 | Evans Daron | CFO | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Jan 23, 2024 | Jan 25, 2024 | ROBERTS BRIAN KENNETH | Chief Medical Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jan 23, 2024 | Jan 25, 2024 | Elam Nevan C | CEO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jan 23, 2024 | Jan 25, 2024 | Hogenhuis Wladimir | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jan 23, 2024 | Jan 25, 2024 | Labrucherie Gil M | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jan 23, 2024 | Jan 25, 2024 | FAUCHET PHILIPPE | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jan 23, 2024 | Jan 25, 2024 | KREHER NERISSA | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jul 3, 2023 | Jul 6, 2023 | ROBERTS BRIAN KENNETH | Chief Medical Officer | Buy | 90.0 | +5,000 | 22.17% | ✗ | $9.5K |
| Jun 23, 2022 | Jun 28, 2022 | Kim Young-Jin | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 23, 2022 | Jun 27, 2022 | FAUCHET PHILIPPE | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 23, 2022 | Jun 27, 2022 | ROBERTS BRIAN KENNETH | Sr VP, Clinic Development | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 23, 2022 | Jun 27, 2022 | Hogenhuis Wladimir | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 23, 2022 | Jun 27, 2022 | Elam Nevan C | CEO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 23, 2022 | Jun 27, 2022 | Labrucherie Gil M | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 23, 2022 | Jun 27, 2022 | KREHER NERISSA | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| May 17, 2022 | May 19, 2022 | ROBERTS BRIAN KENNETH | Sr VP, Clinic Development | Buy | 85.0 | +1,500 | 7.13% | ✗ | $4.9K |
| May 4, 2022 | May 9, 2022 | Labrucherie Gil M | Director | Buy | 95.0 | +52,631 | 5593.09% | ✗ | $200K |
| May 4, 2022 | May 6, 2022 | ROBERTS BRIAN KENNETH | Sr VP, Clinic Development | Buy | 95.0 | +21,052 | 100.00% | ✗ | $80K |
| May 4, 2022 | May 6, 2022 | Labrucherie Gil M | Director | Buy | 95.0 | +52,631 | 111.88% | ✗ | $200K |
| Oct 15, 2021 | May 6, 2022 | Hogenhuis Wladimir | Director | Buy | 95.0 | +32,693 | 100.00% | ✗ | $145K |
| Jun 14, 2021 | Aug 31, 2021 | Elam Nevan C | CEO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Apr 26, 2019 | Jul 28, 2021 | Genexine Inc. | 10% Owner | Buy | 100.0 | +34,482,758 | 60.69% | ✗ | $10M |
| Jul 28, 2021 | Genexine Inc. | 10% Owner | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Jun 14, 2021 | Jul 14, 2021 | Hogenhuis Wladimir | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 14, 2021 | Jul 14, 2021 | FAUCHET PHILIPPE | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 14, 2021 | Jul 14, 2021 | KREHER NERISSA | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 14, 2021 | Jul 14, 2021 | Labrucherie Gil M | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 14, 2021 | Jul 14, 2021 | ROBERTS BRIAN KENNETH | Sr VP, Clinic Development | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 14, 2021 | Jul 14, 2021 | Elam Nevan C | CEO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Mar 8, 2021 | Hogenhuis Wladimir | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Mar 8, 2021 | KREHER NERISSA | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |